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3Abstract
Predefined, researcher-selected outcomes are routinely used as the clinical end-point in
randomised controlled trials (RCTs); however, individualised approaches may be an effective
way to assess outcome in mental health research. The present study describes the
development and evaluation of the Individualised Outcome Measure (IOM), which is a
patient-specific outcome measure to be used for RCTs of complex interventions. IOM was
developed using a narrative review, expert consultation and piloting with mental health
service users (n=20). The final version of IOM comprises two components: Goal Attainment
(GA) and Personalised Primary Outcome (PPO). For GA, patients identify one relevant goal at
baseline and rate its attainment at follow-up. For PPO, patients choose an outcome domain
related to their goal from a predefined list at baseline, and complete a standardised
questionnaire assessing the chosen outcome domain at baseline and follow-up. A feasibility
study indicated that IOM had adequate completion (89%) and acceptability (96%) rates in a
clinical sample (n=84). IOM was then evaluated in an RCT (ISRCTN02507940). GA and PPO
components were associated with each other and with the trial primary outcome. The use
of the PPO component of IOM as the primary outcome could be considered in future RCTs.
Keywords: randomised controlled trial, mental health, personalised measure, individualised
outcome
4Introduction
Randomised controlled trials (RCTs) evaluate the effectiveness of an intervention in relation
to a pre-specified primary outcome (Schulz et al., 2010). Predefining a standardised measure
as a primary outcome has several advantages, including informing the power calculation for
the sample size, reducing post-hoc ‘data fishing’, and supporting meta-analytic aggregation
of findings across studies. However, the use of a single predefined primary outcome to
evaluate complex interventions raises four issues.
First, a range of outcome domains exist (Slade, 2002), and as complex interventions may
impact across this range (Craig et al., 2008), a single predefined outcome measure may not
capture all changes. Second, some measures may become widely used primarily because
they have been used in other RCTs, rather than because of any inherent superiority (Everitt
and Wessely, 2004). Third, pre-specifying the primary outcome for an RCT may not be
clinically informative, as recognised in the developing field of clinimetrics (Feinstein, 1983).
Finally, patients may vary in the importance they attach to different types of outcomes. For
example, the aim of treatment for some people may be symptomatic improvement,
whereas others have social goals (e.g. employment) or personal goals (e.g. to find meaning
in their life) (Slade, 2009). As a result, a predefined outcome measure may not be relevant
to the person receiving the intervention.
A number of patient-centred measures and approaches have been developed to address
these issues, such as Goal Attainment Scaling (GAS) and Target Complaint Approach
(Donnelly and Carswell, 2002). The GAS process was originally developed for mental health
programmes (Kiresuk and Sherman, 1968) and it involves the patient, together with the
clinician, prospectively identifying a number of relevant goals, and then rating their progress
towards each goal along a five-point scale at follow-up. Although each respondent has
different goals, the overall GAS score is standardised so that data can be aggregated and
compared across individuals (McDougall and King, 2007; Turner-Stokes, 2009). GAS has
been effectively used to identify and evaluate outcomes in RCTs in rehabilitation (Graven et
al., 2011; Turner-Stokes et al., 2010) and studies with older adults (Rockwood et al., 2007;
Rockwood et al., 2003). Systematic reviews conclude that GAS shows high sensitivity to
change, reliability and validity when used in chronic healthcare and physical and
5neurological rehabilitation (Hurn et al., 2006; Stevens et al., 2013). A systematic review of
research evaluating the implementation of GAS in occupational health programmes found
that goal setting could be implemented in mental health settings and that goal attainment
was associated with positive change in clinical outcomes (Scott and Haggarty, 1984). GAS
was also found to be an effective clinical tool among patients in psychiatric day care, with
patients with schizophrenia having the highest success rate with 75% achieving a good
outcome (Falloon and Talbot, 1982).
Despite this evidence, fully individualised goal setting is not implemented in randomised
controlled trials in the mental health field. This may be due to operational limitations
associated with GAS (Ertzgaard et al., 2011; King et al., 1999). In particular, goal scaling
relies on a complex formula, making calculations complex and interpretation complicated
(Stevens et al., 2013). Moreover, GAS is based on scaling at baseline and follow-up which
may not fully capture the actual level of goal attainment. Finally, researchers would most
likely be involved in goal selection and scaling in RCTs, and they may not be able to assess
whether the goal is realistic at baseline or rate attainment at follow-up.
The aim of this study was to develop and evaluate a new trans-diagnostic and patient-
valued approach to assessing change in RCTs of complex interventions in mental health, by
using individualised and positively-valued outcome domains. In line with recovery research
(Leamy et al., 2011), the focus was on subjective experiental outcomes rather than clinical
outcomes. The objectives were to develop, pilot, and assess the feasibility of the
Individualised Outcome Measure (IOM), and then to evaluate IOM in an RCT by assessing
whether IOM components 1) capture change over time, 2) co-vary, and 3) are associated
with the predefined primary outcome.
Method
Participants
Participants were recruited from community-based mental health teams in the South
London and Maudsley NHS Foundation Trust (pilot, feasibility, RCT) and 2Gether NHS
Foundation Trust (RCT). Inclusion criteria were being aged 18-65 years, being able to speak
6and understand English, and being sufficiently well to participate in the opinion of the
clinician providing community support. In the RCT, patients were participating in the
REFOCUS Trial (ISRCTN02507940) which had additional inclusion criteria. These were having
a primary clinical diagnosis of psychosis, having no immediate plans for discharge or
transfer, not currently receiving in-patient care, not being in prison, not participating in
another substantial study, and being in regular contact with at least one worker in the team.
Ethical approval was obtained (10/H0807/4).
Measures
The final version of the Individualised Outcome Measure (IOM Version 3) comprised two
components to index individual outcomes: Goal Attainment (GA) and Personalised Primary
Outcome (PPO). The GA component is a variation of GAS, requiring patients to identify one
personally relevant goal which mattered to them, that they thought they could achieve and
which services could help with, at baseline. Patients were asked to identify only one goal as
evidence from mental health research showed respondents can focus on one goal at a time
(Scott and Haggarty, 1984). Having one goal also simplifies assessment of change and aids
interpretability of the findings. At follow-up, the patient rated how successful they were at
reaching their goal on a 5-point Likert scale from 0 (I am further away from my goal) to 4 (I
did even better than expected).
After identifying their goal, patients were invited to complete the PPO component, which is
a novel approach. It requires patients to choose the outcome domain which most closely
maps onto their selected goal from a predefined list. Each domain is associated with one
standardised measure, which patients complete at baseline and again at follow-up.
In IOM Version 1, thirteen outcome domains and associated patient-rated measures were
included in the PPO component. The Activity and Participation Questionnaire (APQ) is a 5-
item measure of social inclusion ranging from 0 to 24 (Coombs et al., 2013). The Short Form
Health Survey (SF-36) is a 36-item measure of functional health and well-being, consisting of
8 scaled scores each with a score range from 0 to 100 (Ware and Sherbourne, 1992). The
Short Health Survey Questionnaire (SF-12) is a 12-item measure of functional health and
well-being, consisting of 2 scaled scores with a score range from 0 to 100 (Jenkinson and
7Layte, 1997). The Empowerment Scale (ES) is a 28-item measure ranging from 1 to 112
(Rogers et al., 1997). The Herth Hope Index (HHI) is a 12-item measure of hope ranging
from 1 to 48 (Herth, 1992). The Rosenberg Self-Esteem Scale (RSES) is a 10-item measure
ranging from 1 to 40 (Rosenberg, 1965), items were recoded so that high scores indicated
higher self-esteem levels. The Stigma Scale (SS) is a 28-item measure of stigma of mental
illness and ranges from 1 to 140, with high scores indicating low stigma (King et al., 2007).
The Meaning of Life Questionnaire (MLQ) is a 10-item measure ranging from 1 to 70 (Steger
et al., 2006). MLQ comprises two subscales: Search for and Presence of meaning of life, and
only the Presence subscale was used. The MOS Social Support Survey (MOS) is a 21-item
measure ranging from 1 to 85 (Sherbourne and Stewart, 1991). The Community Integration
Measure (CIM) is a 10-item measure ranging from 1 to 50 (McColl et al., 2001). The
Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) is a 14-item measure of wellbeing
ranging from 1 to 70 (Tennant et al., 2007). The Service user Perception of Functioning
Scale (PPFS) is a 6-item measure with ratings for both community functioning and cognition,
rated ranging from 1 to 30 (Horn et al., 2012). The Manchester Short Assessment of Quality
of Life (MANSA) is a 12-item measure ranging from to 84 (Priebe et al., 1999).
Two additional measures were used. The Mental Health Confidence Scale (MHCS) is a 16-
item measure of empowerment ranging from 1 to 96 with good psychometric properties
(Carpinello et al., 2000; Castelein et al., 2008). The Questionnaire about the Process of
Recovery (QPR) was the primary outcome of the REFOCUS trial (Neil et al., 2009; Slade et
al., 2011). This is a 22-item patient-rated assessment of recovery, with each item rated on a
five-point scale from 0 to 4. An overall score was extrapolated by summing 15 of the original
22 items (Law H et al., 2014). All scales were coded so that a high score indicated a positive
outcome.
The two-stage development process
Development and piloting
The PPO was developed using a narrative review of outcome domains in mental health
(Bjorkman and Svensson, 2005; Myers et al., 2005; National Institute for Mental Health in
England, 2008; Rush Jr, 2008; Slade, 2009) with specific emphasis on domains valued by
patients (Faulkner and Layzell, 2000; Perkins and Repper, 2003; Rosenheck et al., 2005). For
8each domain, a related outcome measure was sought. This produced the initial version of
IOM Version 1, which was consulted on with the REFOCUS advisory boards, comprising a
Lived Experience Advisory Panel (LEAP) of service users and carers, topic-specific experts, a
virtual advisory panel of service users, researchers and other stakeholders with an interest
in black and minority ethnic mental health, and an International Advisory Board of
international experts. The consultation focused on identifying outcome domain omissions,
measures for outcome domains which did not have identified measures as well as to
improve the content, order and format of the PPO, which consisted of 13 outcome domains
and corresponding measures. Following this consultation, IOM Version 2 was finalised.
A pilot study was, subsequently, undertaken with a convenience sample of 20 patients, to
assess their experience of completing IOM Version 2. Characteristics of pilot study
participants are shown in Table 1.
Insert Table 1 here
The pilot was conducted to identify any necessary change which may improve IOM.
Informed consent was obtained and patients were paid £10 for their participation. All
patients were able to complete and provide information on the IOM. Following the pilot,
three measures of the PPO (APQ, SF-36 and SF-12) were deleted as they were not chosen by
any respondent. Additionally, the Empowerment Scale was replaced with the Mental Health
Confidence Scale. No changes were necessary for the GA component. Table 1 shows the list
of ten outcome domains and their associated measures which constituted IOM Version 2.
Insert Table 2 here
Feasibility
We then assessed the feasibility of IOM Version 3 using a convenience sample of 84 current
mental health patients, whose characteristics are shown in Table 1. They completed IOM at
baseline and at 3-month follow-up, and rated their experience of completing IOM.
Participants were paid £10 for each round of assessment.
9A total of 75 (89%) patients were able to identify a goal, a relevant outcome domain, and
complete the associated PPO measure. The time to identify a goal ranged between 1 and 5
minutes (median = 1, iqr = 1). We found that 64 (85%) patients reported the goal was ‘very’
or ‘extremely’ important to them while only 3 (4%) were not happy about being asked. All
ten PPO domains and their associated measures were selected and completed (Table 2,
column 4). At follow-up, 55 (73%) patients completed both IOM components. There was no
association between attrition and any of the sociodemographic variables. For the GA
component, 8 (15%) rated the goal as Fully Achieved, 28 (51%) as Partly Achieved and 19
(35%) as Not Achieved. Finally, 36 (65%) individuals rated their original goal as still Very or
Extremely important.
Evaluation in an RCT
We then evaluated IOM Version 3 as an outcome measure in the REFOCUS Trial. The trial
evaluated a team-based intervention intended to impact on the content and process of care
(Slade et al., 2011). The intervention was intended to lead to more collaborative staff-
patient relationships, and greater staff-focus on patient values, strengths, and goal-striving.
The intended benefits were more patient-centred and recovery-oriented care, and this
emphasis on individualised care in this team-based and trans-diagnostic intervention meant
that the use of a predefined and invariant primary outcome was problematic in capturing
the outcome domain relevant to each patient. The QPR was the predefined primary
outcome.
Participating teams (n=27) were randomly allocated to control (n=13, treatment as usual) or
intervention (n=14, treatment as usual plus REFOCUS Intervention). A random sample of 15
patients was recruited from each participating team, and after giving informed consent,
they completed a set of measures including QPR and IOM Version 3 at baseline and at one-
year follow-up. Participants were paid £10 for each round of assessment.
Data analysis
The effectiveness of the intervention did not differ between arms (Slade et al., in press), so
data from both trial arms were pooled to address our hypotheses. We explored the
relationship between attrition (missing vs. present) and socioeconomic variables of gender
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age, ethnicity, marital status, education and accommodation type for the feasibility study
and the trial. Missing data across the outcome scales were pro-rated when less than 20% of
items were left blank.
Prior to conducting our analysis, we recoded the IOM components to facilitate analysis. To
avoid small cell counts, GA was recoded so that ‘successful’ and ‘even better than expected’
were coded as Fully Achieved, ‘some progress’ was coded as Partly Achieved, and ‘no
progress’ and ‘further away from the goal’ were coded as Not Achieved. To combine scores
of the PPO, we standardised each measure using z-scores based on population norms from
previous research.
Objective 1 - change over time
In order to test if the difference was significantly different from 0, we conducted a
regression analysis with no predictors on the PPO difference score between baseline and
follow-up. Subsequently, we assessed whether change on the PPO was clinically meaningful
by implementing the Reliable Change Index (RCI) approach following the Jacobson and
Truax’s guidelines (Jacobson and Truax, 1991):
(x2-x1)/sqrt(2*(s*sqrt(1-rxx))2)
where rxx is the Cohen’s alpha (i.e., reliability) value and s is the scale standard deviation
based on population values. RCI is a standardised measure of change and scores greater
than the critical value (i.e., +/-1.96) correspond to reliable change (Zahra and Hedge, 2010).
Using these cut-off points, we could group patients as having ‘Improved’, ‘Not changed’, or
‘Declined’.
Objective 2 – co-variation
To assess whether the two IOM components are associated and tap onto the same
construct, we regressed the PPO follow-up score on GA while adjusting for baseline
standardised scores.
Objective 3 – relationship with primary outcome
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We assessed the relationship of the two IOM component with the REFOCUS trial predefined
primary outcome of QPR by regressing the QPR change score separately onto the PPO
change scores and GA.
In all regression analyses, we accounted for clustering at the team level by conducting
random effects regression analyses with maximum likelihood estimation using the ‘xtmixed’
command in Stata 11. Site and trial arm were entered as covariates in the model in order to
reflect the study design. Bonferroni corrections were implemented to adjust for multiple
pairwise comparisons when appropriate.
RESULTS
At baseline, 340 (86%) patient participants in the RCT completed both components of the
IOM. Table 1 summarises their sociodemographic characteristics. Patients with complete
IOM at baseline were more likely to be White British (vs. other; chi2(1)=8.5, p=.004), to live in
private accommodation (vs. supported; chi2(1)=4.6, p=.03) and to have formal qualifications
(vs. no qualification; chi2(1)=20.9, p<.001).
At one-year follow-up, 239 (of 340) patients completed both IOM components. Patients
with complete information at follow-up were more likely to have formal qualifications (vs.
no qualification; chi2(1)=6.7, p=.01) and to be younger (t(374)=2.4, p=.02). All ten PPO domains
and their associated measures were selected and completed (Table 1, column 5). The goal
was rated as Fully Achieved by 63 (26%) patients, 113 (47%) rated it as Partly Achieved while
63 (26%) reported having made No Progress.
Objective 1: change over time
The regression analysis (average cluster size = 9, range: 1 to 13) indicated that the change
score on the PPO between baseline and follow-up was not different from 0 (z=1.3, p=.18,
n=239). The RCI approach indicated that 79% patients did not change over time (Table 3).
Insert Table 3 here
Objective 2: co-variation
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Analyses were conducted on all 239 participants with complete information on the IOM. A
regression analysis across all 27 clusters (average cluster size = 9, range 1 to 13) showed an
association between GA and PPO (2(2)=13.8, p=.001; n=239). Compared to patients who had
made No Progress, those who had Partly (b=.32, 95%CI: .09 to .56, z=2.7, p=.007) or Fully
Achieved their goal (b=.50, 95%CI: .23 to .77, z=3.7, p<.001) had higher PPO scores at follow-
up, while adjusting for baseline scores and accounting for multiple testing.
Objective 3: relationship with primary outcome
Regression analysis on all 237 patients with complete information on IOM and QPR (average
cluster size = 9, range 1 to 13) showed that the PPO and QPR change scores were positively
associated (b=3.3, 95%CI: 2.3 to 4.4, z=6.2, p<.001). Similarly, regression analysis across all
27 clusters (average cluster size = 9, range 1 to 13) showed that GA was associated with
follow-up QPR scores (2(2)=12.4, p=.002). In particular, patients who had Partly (b=3.0,
95%CI: 0.8 to 5.2, z=2.6, p=.008) or Fully Achieved their goal (b=4.3, 95%CI: 1.9 to 6.8, z=3.4,
p=.001) reported greater recovery scores than those who had Not Achieved their goals,
even after adjusting for multiple testing.
DISCUSSION
Following growing consensus that individualised approaches may be an effective way to
assess outcome in mental health research (Slade, 2009), a new measure of individualised
outcome for use as a clinical end-point in RCTs was developed, by literature review, expert
consultation, piloting, assessment of feasibility and then evaluation in the context of an RCT.
The IOM has two components, both of which had adequate acceptability and completion
rates. Evaluation in an RCT showed that IOM could be used to differentiate between
patients who changed versus those who did not change, that the two components (GA and
PPO) co-vary, and that both were associated with change in the predefined primary
outcome for the trial.
For GA, the majority of respondents (66% feasibility study, 72% RCT) reported having made
at least some progress on their goal at follow-up. These figures are in line with those
observed in previous studies in mental health and rehabilitation (Hurn et al., 2006; Scott and
Haggarty, 1984; Stevens et al., 2013). For example, 63% of patients with schizophrenia were
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found to have made good progress on their goal at 6-month follow-up (Falloon and Talbot,
1982). These results suggest that the GA component, which is a variation of the GAS, is as
effective as the original version at capturing achievement.
The PPO component did not capture any statistical or clinically meaningful change across
time (objective 1). Nonetheless, no change was observed on the REFOCUS trial primary
outcome (Slade et al., in press), which suggests that change did not occur in the 12-month
period. Hence, implementation and replication in a future trial is needed. PPO scores at
follow-up were associated with Goal Attainment (objective 2), which indicates the two IOM
components tap onto overlapping domains as originally intended. The PPO change scores
were positively associated with change scores on QPR (objective 3). Thus, it appears to
capture change levels in similar fashion to that exhibited by a standardised questionnaire.
Finally, patients who had Fully or Partly achieved their goal were more likely to report
improved QPR scores than those who had not achieved their goal (objective 3). These
results are in line with evidence that GAS scores were positively associated with
standardised measures of progress in rehabilitation (de Beurs et al., 1993; Hurn et al., 2006).
One limitation is the fact that we cannot ascertain whether goal attainment leads to a
greater sense of recovery or whether increased recovery leads to goal attainment as GA was
assessed at follow-up only. Previous research indicates that goal attainment predicts
progression in recovery (Clarke et al., 2009), and future studies implementing a mixed-
method design may help us to further understand this association. Patients were assumed
to be failing at baseline but this could not be corroborated which represents a limitation.
Future studies may incorporate baseline assessment to index change on this component,
although this would require more complex calculations.
Combining the different measures of the PPO list may be criticised for potentially leading to
biased results; however, we used a norm-based standardisation process which has been
found to overcome these issues (Van Cleave et al., 2011). Finally, even though variations of
the original RCI exists which take into account the regression to the mean phenomenon
(Wise, 2004), research showed that the original RCI approach represents an optimal
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measure of change (Marsden et al., 2011; McGlinchey et al., 2002). The main strength of the
study was the large and clinically representative sample recruited for an RCT in mental
health, which renders our findings generalisable.
In summary, analysis of feasibility and evaluation of the IOM indicated that this approach
can be implemented as an individualised outcome in RCTs for complex interventions in
mental health. As the PPO provides an ecologically valid, standardised and more easily
comparable approach to outcome measurement, we recommend the PPO component be
retained, with the addition of the goal-identification element of GA as selecting a goal
facilitates identifying a relevant outcome domain. Future research should further assess the
psychometric properties (e.g., internal consistency, construct validity and test-retest
reliability) of the PPO and establish whether it could be implemented in different types of
intervention in mental health research.
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Table 1. Sociodemographic characteristics of participants
Pilot study Feasibility study RCT evaluation
N (complete data) 20 75 340
Age (years) 40.9 years 42.3 (10.7) 43.5 (10.8)
Gender
Male 14 (70) 51 (68) 214 (63)
Female 6 (30) 24 (32) 125 (37)
Ethnicity
White 10 (50) 35 (47) 203 (60)
Black 6 (30) 32 (43) 85 (25)
Other 4 (20) 8 (11) 50 (15)
Diagnosis
Psychosis 340 (100)
Schizophrenia 5 (26) 35 (50)
Bipolar disorder 5 (26) 15 (21)
Depression 1 (5) 1 (1)
Mixed 4 (21) 14 (20)
Other 4 (21) 5 (7)
20
Table 2. PPO domains and baseline completion rates for Feasibility study (n=75) and evaluation in an RCT 3 (n=340)
Outcome domain descriptions given to
participants
Outcome domain
being described
Associated measure Feasibility
study
Evaluation in an RCT
N (%) N (%) Raw mean(SD)
1. Feeling more hopeful about the future Hope Herth Hope Index 7 (9) 47 (14) 36.14 (5.1)
2. Feeling more in control of my life Empowerment Mental Health Confidence Scale 6 (8) 26 (8) 66.95 (17.1)
3. Feeling more positive about myself Self-esteem Rosenberg Self-Esteem Scale 11 (15) 61 (18) 26.32 (4.4)
4. Feeling better treated by other people Stigma Stigma Scale 2 (3) 7 (2) 51.27 (13.2)
5. Feeling like you have meaning in your life Meaning of life Meaning of Life Questionnaire 7 (9) 42 (12) 24.45 (7.1)
6. Feeling supported by other people Social support MOS Social Support Survey 3 (4) 8 (2) 71.53 (13.9)
7. Feeling part of the community Community
integration
Community Integration Measure 3 (4) 11 (3) 30.46 (8.1)
8. Feeling better about your life Wellbeing Warwick-Edinburgh Mental Well-
being Scale
8 (11) 39 (12) 45.26 (9.7)
9. Being able to manage day-to-day life Daily functioning Service user Perception of
Functioning Scale
11 (15) 28 (8) 16.71 (3.6)
10. Having a better quality of life Quality of life Manchester Short Assessment of
Quality of Life
17 (23) 71 (21) 55.90 (10.2)
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Table 3. Reliable Change Index at one-year RCT follow-up (n=239)
Cut-off
(RCI=1.96)
Change status n (%)
Declined No change Improved
HHI 6.78 2 (6) 26 (79) 5 (15)
MHCS 8.69 5 (26) 8 (42) 6 (32)
RSES 7.30 1 (2) 42 (89) 4 (9)
Stigma 15.39 0 (0) 3 (100) 0 (0)
MLQ presence 8.34 1 (4) 24 (86) 3 (11)
MOS 11.62 2 (33) 4 (67) 0 (0)
CIM 7.70 0 (0) 3 (75) 1 (25)
WEMWBS 8.64 3 (12) 21 (84) 1 (4)
PPFS 2.36 2 (9) 14 (64) 6 (27)
MANSA 11.03 4 (8) 44 (85) 4 (8)
Total 20 (8) 189 (79) 30 (13)
